Clinical Scorecard: Guidelines for Staging and Restaging in Oncology Using FDG-PET/CT: Recommendations from the European Society for Hybrid, Molecular, and Translational Imaging

At a Glance

Key Highlights

• [18F]FDG-PET/CT offers superior diagnostic accuracy compared to conventional imaging in sensitivity and specificity for many cancers, impacting clinical management significantly.
• It is essential for staging, detecting recurrent tumors early, guiding biopsy and surgical planning, and monitoring response to chemotherapy, immunotherapy, and radiotherapy.
• Combining PET with diagnostic CT (with or without contrast) and other modalities like MRI enhances anatomical correlation and comprehensive tumor assessment.

Guideline-Based Recommendations

Diagnosis

• Select patients for [18F]FDG-PET/CT based on clinical criteria and evidence of superior diagnostic accuracy over conventional imaging.
• Use [18F]FDG-PET/CT to evaluate extent of disease for staging and to detect unknown primary tumors or recurrence when tumor markers are elevated.
• Interpret PET findings in context with CT and consider potential false positives from inflammation or infection.

Management

• Incorporate [18F]FDG-PET/CT findings into treatment planning including chemotherapy, immunotherapy, radiotherapy, and surgical approaches.
• Use PET/CT to identify non-responding tumors early to allow timely modification of treatment.
• Perform low-dose CT for attenuation correction and diagnostic CT with or without contrast for anatomical correlation during PET/CT.

Monitoring & Follow-up

• Apply PET Response Evaluation Criteria in Solid Tumors (PERCIST) integrating metabolic activity for comprehensive assessment of treatment response.
• Cover imaging from skull base to mid-thigh for most cancers; extend to full body if lower limb metastases are suspected.
• Use structured reporting to provide clear, actionable information to referring clinicians.

Risks

• Be aware of false negatives in subcentimeter nodules (<8–10 mm) due to PET spatial resolution limits.
• Consider false positives from inflammatory or infectious processes affecting glucose metabolism.
• Balance radiation exposure from combined PET and CT scans with clinical benefit.

Patient & Prescribing Data

Patients with high incidence cancers such as lung cancer, lymphoma, head and neck cancer, breast cancer, and colorectal cancer undergoing staging or treatment evaluation

[18F]FDG-PET/CT significantly alters therapeutic management in approximately one-third of patients by detecting additional metastases and enabling early detection of treatment non-response.

Clinical Best Practices

• Carefully evaluate appropriateness of [18F]FDG-PET/CT for each patient based on clinical indication and evidence.
• Combine PET with diagnostic CT and, when available, MRI to improve diagnostic accuracy and anatomical localization.
• Use PET/CT for biopsy site selection and surgical planning to optimize tumor removal.
• Apply PERCIST criteria alongside RECIST for comprehensive treatment response evaluation.
• Ensure structured and clear reporting to facilitate clinical decision-making.

References

• European Society for Hybrid, Molecular, and Translational Imaging Guidelines
• PERCIST Criteria for PET Response Evaluation